Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SToP-AD: Suvorexant for Alzheimer's Disease Prevention
NCT04629547Phase 2Recruiting
- Sponsor
- University of Minnesota
- Start
- May 2022
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of suvorexant in Alzheimer's disease (AD) (2 arms), sponsored by University of Minnesota. Primary endpoint: Change from baseline in Amyloid-β accumulation measured by plasma pT217/T217. Started May 2022; status: recruiting.
02
Drugs
suvorexant
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04629547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04629547.